FANCA deficiency has been shown to sensitize ovarian and prostate cancers to PARPis, demonstrating the existence of synthetic lethality of FA proteins other than BRCA1/2 with PARPi treatment53. The gene discussed is FANCA; the disease is prostate carcinoma.